Atacand (Candesartan Cilexetil) - Summary

ATACAND SUMMARY

ATACAND (candesartan cilexetil), a prodrug, is hydrolyzed to candesartan during absorption from the gastrointestinal tract. Candesartan is a selective AT₁ subtype angiotensin II receptor antagonist.

ATACAND is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.

ATACAND NEWS HIGHLIGHTS

Media Articles Related to Atacand (Candesartan Cilexetil)

candesartan, Atacand
Source: MedicineNet irbesartan Specialty [2005.10.16]

Treatment Of Lung Hypertension Does Not Help Patients With Chronic Bronchitis
Source: Respiratory / Asthma News From Medical News Today [2008.08.29]

Possible Association Between High Levels Of Uric Acid And Hypertension
Source: Hypertension News From Medical News Today [2008.08.28]

Allopurinol May Lower Blood Pressure In Teens With Hypertension
Source: Hypertension News From Medical News Today [2008.08.28]

Drug Designed To Lower Uric Acid Levels May Be Useful For Hypertension
Source: Blood / Hematology News From Medical News Today [2008.08.27]

more>>

Published Studies Related to Atacand (Candesartan Cilexetil)

A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantation. [2006.10]

Candesartan- and atenolol-based treatments induce different patterns of carotid artery and left ventricular remodeling in hypertension. [2006.09]

Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals. [2006]

Candesartan reduces urinary fatty acid-binding protein excretion in patients with autosomal dominant polycystic kidney disease. [2005.10]

Angiotensin II receptor blocker-induces blunted taste sensitivity: comparison of candesartan and valsartan. [2005.08]

more>>

Clinical Trials Related to Atacand (Candesartan Cilexetil)

Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age [Active, not recruiting]

Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide [Completed]

Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH [Completed]

DIabetic Retinopathy Candesartan Trials. [Active, not recruiting]

Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg [Completed]

more>>